REV-ERB raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
=== Availability === Methenamine is approved and available in the United States. Only methenamine hippurate, the twice-daily formulation, is available as a prescription drug in the United States. Of 38 countries that were surveyed in one study, methenamine was available in seven of them. In any case, methenamine was marketed as a prescription drug widely throughout the world in 2004. The topical form of methenamine for hyperhidrosis has been marketed only in certain countries, including Austria, Canada, Germany, Luxembourg, and Switzerland.
===== Tuberculosis ===== Infants whose mothers have suspected untreated tuberculosis (TB) should be isolated from their mothers to reduce the risk of transmission. As such, these infants should not be breastfed during this time and until the mother has been treated appropriately for 2 weeks and is no longer contagious. However, these infants may be fed expressed breastmilk from their mother. Transmission of TB through breastmilk, without an isolated breast infection caused by the Tuberculosis bacteria (Mycobacterium tuberculosis), has never been documented in the scientific literature. Mothers who do have an isolated breast infection caused by Mycobacterium tuberculosis, termed tuberculous mastitis, should not feed their infants with their own breastmilk, even if it is fed by bottle.
GABAergic pro-drugs include chloral hydrate, which is metabolised to trichloroethanol, which then acts via the GABAA receptor. The plant kava contains GABAergic compounds, including kavain, dihydrokavain, methysticin, dihydromethysticin and yangonin.
In chemistry, there are three definitions in common use of the word "base": Arrhenius bases, Brønsted bases, and Lewis bases. All definitions agree that bases are substances that react with acids, as originally proposed by G.-F. Rouelle in the mid-18th century. In 1884, Svante Arrhenius proposed that a base is a substance which dissociates in aqueous solution to form hydroxide ions OH−. These ions can react with hydrogen ions (H+ according to Arrhenius) from the dissociation of acids to form water in an acid–base reaction. A base was therefore a metal hydroxide such as NaOH or Ca(OH)2. Such aqueous hydroxide solutions were also described by certain characteristic properties. They are slippery to the touch, can taste bitter, and change the color of pH indicators (e.g., turn red litmus paper blue). In water, by altering the autoionization equilibrium, bases yield solutions in which the hydrogen ion activity is lower than it is in pure water, i.e., the water has a pH higher than 7.0 at standard conditions. A soluble base is called an alkali if it contains and releases OH− ions quantitatively. Metal oxides, hydroxides, and especially alkoxides are basic, and conjugate bases of weak acids are weak bases. Bases and acids are seen as chemical opposites because the effect of an acid is to increase the hydronium (H3O+) concentration in water, whereas bases reduce this concentration. A reaction between aqueous solutions of an acid and a base is called neutralization, producing a solution of water and a salt in which the salt separates into its component ions.
It has been claimed that Russian security services organized a number of denial of service attacks as a part of their cyber-warfare against other countries, most notably the 2007 cyberattacks on Estonia and the 2008 cyberattacks on Russia, South Ossetia, Georgia, and Azerbaijan. One identified young Russian hacker said that he was paid by Russian state security services to lead hacking attacks on NATO computers. He was studying computer sciences at the Department of the Defense of Information. His tuition was paid for by the FSB. Russian, South Ossetian, Georgian and Azerbaijani sites were attacked by hackers during the 2008 South Ossetia War. In October 2016, Jeh Johnson the United States Secretary of Homeland Security and James Clapper the U.S. Director of National Intelligence issued a joint statement accusing Russia of interfering with the 2016 United States presidential election. The New York Times reported the Obama administration formally accused Russia of stealing and disclosing Democratic National Committee emails. Under U.S. law (50 U.S.C.Title 50 – War and National Defense, Chapter 15 – National Security, Subchapter III Accountability for Intelligence Activities) there must be a formal Presidential finding prior to authorizing a covert attack. Then U.S. vice president Joe Biden said on the American news interview program Meet The Press that the United States will respond. The New York Times noted that Biden's comment "seems to suggest that Mr. Obama is prepared to order – or has already ordered – some kind of covert action".
Sources: en.wikipedia.org
== Further reading == Thakkar, Santosh V.; Allegre, Kevin M.; Joshi, Sangeeta B.; Volkin, David B.; Middaugh, C. Russell (2012). "An application of ultraviolet spectroscopy to study interactions in proteins solutions at high concentrations". Journal of Pharmaceutical Sciences. 101 (9): 3051–3061. Bibcode:2012JPhmS.101.3051T. doi:10.1002/jps.23188. ISSN 0022-3549. PMID 22581726. Scott Huffman, Keyur Soni and Joe Ferraiolo UV-Vis Based Determination of Protein Concentration: Validating and Implementing Slope Measurements Using Variable Pathlength Technology by September 2014 http://www.bioprocessintl.com/manufacturing/antibody-non-antibody/uv-vis-based-determination-protein-concentration-validating-implementing-slope-measurements-using-variable-pathlength-technology/
== Distribution == Geography cones are common. They occur in the Red Sea and in the Indian Ocean off Chagos, Réunion, Madagascar, Mauritius, Mozambique and Tanzania. They are indigenous to the reefs of the Indo-Pacific region, except for Hawaii, and off Australia (the Northern Territory, Queensland, Western Australia). Since the distribution of C. geographus can largely be explained by the temperature of its habitat, alterations due to climate change are predicted to impact its distribution in the following decades. The seas around Southeast Asia are in parts predicted to have a higher suitability by 2090, while parts of Australia and Africa's eastern coast could become less suitable.
=== Pharmacodynamics === Nalorphine acts at two opioid receptors — the μ-opioid receptor (MOR) where it has antagonistic effects, and at the κ-opioid receptor (KOR) (Ki = 1.6 nM; EC50 = 483 nM; Emax = 95%) where it exerts high-efficacy partial agonist/near-full agonist characteristics.
Elaunin (Greek verb ἐλαύνω "I steer") is a component of elastic fibers formed from deposition of elastin between oxytalan fibers. It is found in the periodontal ligament and the connective tissue of the dermis, particularly in association with sweat glands.
==== Cancer immunotherapy ==== In 1995, Robert Conry demonstrated that intramuscular injection of naked RNA encoding carcinoembryonic antigen elicited antigen-specific antibody responses. Then, it was elaborated by demonstrating that dendritic cells(DCs) exposed to mRNA coding for specific antigens or to total mRNA extracted from tumor cells and injected into tumor-bearing mice induced T cell immune responses and inhibited the growth of tumors. Then, researchers started to approach mRNA transfected DCs using vaccines based on ex vivo IVT mRNA-transfected DCs. Meanwhile, Argos Therapeutics had initiated a Phase III clinical trial using DCs with advanced renal cell carcinoma in 2015 (NCT01582672) but it was terminated due to the lack of efficacy. For further application, IVT mRNA was optimized for in situ transfections of DCs in vivo. It improved the translation efficiency and stability of IVT mRNA and enhanced the presentation of the mRNA-encoded antigen on MHC class I and II molecules. Then, they found out that the direct injection of naked IVT mRNA into lymph nodes was the most effective way to induce T cell responses. Based on this discovery, first-in-human testing of the injection of naked IVT mRNA encoding cancer antigens by BioNTech has started with patients with melanoma (NCT01684241). Recently, the new cancer immunotherapy, the combining of self-delivering RNA(sd-rxRNA) and adoptive cell transfer(ACT) therapy, was invented by RXi Pharmaceuticals and the Karolinska Institute.
Sources: en.wikipedia.org
Compared to the United States, which has a greater supply of molybdenum in the soil, people living in those areas have about 16 times greater risk for esophageal squamous cell carcinoma. Molybdenum deficiency has also been reported as a consequence of non-molybdenum supplemented total parenteral nutrition (complete intravenous feeding) for long periods of time. It results in high blood levels of sulfite and urate, in much the same way as molybdenum cofactor deficiency. Since pure molybdenum deficiency from this cause occurs primarily in adults, the neurological consequences are not as marked as in cases of congenital cofactor deficiency. A congenital molybdenum cofactor deficiency disease, seen in infants, is an inability to synthesize molybdenum cofactor, the heterocyclic molecule discussed above that binds molybdenum at the active site in all known human enzymes that use molybdenum. The resulting deficiency results in high levels of sulfite and urate, and neurological damage.
=== 30 November === Ursula von der Leyen, president of the European Commission, suggested the creation of a UN court to investigate war crimes committed by Russia. Russia does not recognize the International Criminal Court, so the European Commission proposed two possible alternative ways to hold Russia accountable: either to create a court that would be set up by international treaties, or to create an international court with a number of judges from several countries. She estimated the war damage to Ukraine is about 600 billion Euros. She proposed a financial plan to help pay for this. She pointed out that the EU had frozen 300 billion Euros worth of Russian central bank reserves and 20 billion Euros worth of money belonging to Russian oligarchs, which she suggested should be invested. The investments could be given to Ukraine when sanctions are lifted. The original statement by Ursula von der Leyen included a claim that 100,000 Ukrainian soldiers and 20,000 Ukrainian civilians have been killed so far in the war. This angered Ukrainian military officials, who said that the death toll was classified information. In response, the European Commission edited the video of von der Leyen's speech to remove this information. Official publications of the text of the speech were also edited to omit the numbers.
Cancer is a change in the cellular processes that cause a tumour to grow out of control. Cancerous cells sometimes have mutations in oncogenes, such as KRAS and CTNNB1 (β-catenin). Analysing the molecular signature of cancerous cells—the DNA and its levels of expression via messenger RNA—enables physicians to characterise the cancer and to choose the best therapy for their patients. As of 2010, assays that incorporate an array of antibodies against specific protein marker molecules are an emerging technology; there are hopes for these multiplex assays that could measure many markers at once. Other potential future biomarkers include micro RNA molecules, which cancerous cells express more of than healthy ones. Cancer is a disease with excessive molecular causes and constant evolution. There's also heterogeneity of disease even in an individual. Molecular studies of cancer have proved the significance of driver mutations in the growth and metastasis of tumors. Many technologies for detection of sequence variations have been developed for cancer research. These technologies generally can be grouped into three approaches: polymerase chain reaction (PCR), hybridization, and next-generation sequencing (NGS). Currently, a lot of PCR and hybridization assays have been approved by FDA as in vitro diagnostics. NGS assays, however, are still at an early stage in clinical diagnostics. To do the molecular diagnostic test for cancer, one of the significant issue is the DNA sequence variation detection.
== Adverse effects == The most common adverse effects are headache, hypothyroidism, cardiac conduction changes, gastrointestinal reactions (including cramps, nausea/vomiting and diarrhoea or constipation), gallstones, reduction of insulin release, hyperglycemia or sometimes hypoglycemia, and (usually transient) injection site reactions. Slow heart rate, skin reactions such as pruritus, hyperbilirubinemia, hypothyroidism, dizziness and dyspnoea are also fairly common (more than 1%). Rare side effects include acute anaphylactic reactions, pancreatitis and hepatitis. Some studies reported alopecia in those who were treated by octreotide. Rats which were treated by octreotide experienced erectile dysfunction in a 1998 study. A prolonged QT interval has been observed, but it is uncertain whether this is a reaction to the medication or the result of an existing illness.
==== United States ==== DOBU is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.